{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-25-000178","form_type":"8-K","ticker":null,"cik":"0001708331","company_name":"Virpax Pharmaceuticals, Inc.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.526873+00:00","generated_at":"2026-05-27T01:42:21.877435+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Virpax appoints Charn Deol to board; Jaydriane Panis resigns","bullets":["Jaydriane Panis resigned from board on Feb 3, 2025; Charn Deol appointed Feb 5, 2025.","Deol appointed Chair of Audit Committee, member of Compensation and Nominating Committees.","Deol receives CAD $3,000/month consulting fee payable to Spiral Investment Corp., his company.","Deol has over 35 years public company experience, currently director/CFO at several companies."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-25-000178","json":"https://secwatch.observer/filing/0001731122-25-000178.json","markdown":"https://secwatch.observer/filing/0001731122-25-000178.md","text":"https://secwatch.observer/filing/0001731122-25-000178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000178/0001731122-25-000178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000178/e6344_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:42:21.877435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02bfd85602","claim":"Jaydriane Panis resigned as Director at Virpax Pharmaceuticals, Inc..","evidence_excerpt":"Jaydriane (Jay) Panis, who resigned from the Board on February 3, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000178/0001731122-25-000178-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fb6d08d69a","claim":"Charn Deol was appointed as Director at Virpax Pharmaceuticals, Inc..","evidence_excerpt":"appointed Mr. Charn Deol as an independent director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000173112225000178/0001731122-25-000178-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}